For many years, cancer has largely been explained as a genetic disease—something driven primarily by mutations in DNA. While genetics certainly play a role, this explanation alone does
not fully answer why cancer develops, why it progresses differently from person to person, or why outcomes can vary so widely.

An expanding body of research points to another important layer: cancer as a disease of metabolism. This perspective, often referred to as the metabolic theory of cancer, shifts the focus from genetics alone to how the body produces energy, regulates blood sugar, manages inflammation, and responds to stress.

Looking at cancer through this metabolic lens invites an empowering question: Can the way we nourish the body influence health, resilience, and healing?

How Diet Shapes Health—or Illness

Every cell in the body requires energy to function. Under healthy conditions, cells generate energy primarily through the mitochondria—often called the “power plants” of the cell. These
structures efficiently convert nutrients and oxygen into usable fuel.

However, research has shown that many cancer cells produce energy differently. Instead of relying on efficient mitochondrial pathways, cancer cells often depend heavily on glucose (sugar)
for fuel—even when oxygen is available. This phenomenon, known as the Warburg Effect, was first described in the 1920s and continues to be widely studied today.

Diet directly influences:

• Blood sugar and insulin levels
• Inflammation and oxidative stress
• Hormonal signaling
• Mitochondrial health and energy production

Over time, diets that chronically elevate blood sugar and insulin—especially in the context of stress, inflammation, and nutrient depletion—may create an internal environment that places
strain on normal cellular function.

This does not mean diet “causes” cancer. Rather, it highlights an important concept: Nutrition helps shape the internal terrain of the body—either supporting balance and
resilience, or contributing to metabolic stress.

The Metabolic Theory of Cancer, Explained Simply

The metabolic theory proposes that cancer begins, at least in part, with impaired cellular energy
metabolism, particularly within the mitochondria. When normal energy pathways are disrupted,
cells may adapt by relying more heavily on fermentation of glucose for fuel.

Researchers studying cancer metabolism have consistently observed that cancer cells tend to
show:

• Mitochondrial dysfunction
• Increased glucose dependence
• Reduced ability to use fat and ketones efficiently

This understanding reframes cancer not only as a genetic condition, but also as a metabolic disease influenced by environment, nutrition, and lifestyle factors.

Importantly, this perspective does not deny the role of genetics. Instead, it recognizes that metabolism and genetics interact, and that metabolic stress may influence how genetic mutations
express themselves.

Why Nutrition Matters in a Metabolic Approach

If cancer cells rely heavily on glucose and insulin-driven signaling for growth, while healthy cells retain more metabolic flexibility, nutrition becomes a meaningful area of support.

Metabolic nutrition strategies aim to:

• Stabilize blood sugar and insulin
• Reduce chronic inflammation
• Support mitochondrial function
• Improve metabolic flexibility

One approach that has received growing attention in research is carbohydrate restriction, including ketogenic-style diets. These diets shift the body toward using fat and ketones as a
primary fuel source rather than glucose.

Studies suggest that many healthy cells can adapt well to ketones, while cancer cells often struggle to do so efficiently. This difference may create a metabolic environment that supports
healthy tissue while placing stress on cancer metabolism—particularly when used alongside conventional treatments under appropriate medical guidance.

What the Research Shows

It is important to be clear and responsible: nutrition alone is not a cure for cancer. However, research increasingly supports the idea that metabolic strategies may serve as valuable adjuncts
to standard care.

Clinical and preclinical studies have explored ketogenic and low-carbohydrate diets in cancer contexts, noting potential benefits related to:

• Improved metabolic markers
• Reduced insulin signaling
• Support for energy and strength
• Enhanced tolerance to certain treatments

These findings reinforce a key principle:

The metabolic environment of the body matters—especially during illness.

A Perspective Rooted in Empowerment, Not Blame

A metabolic approach to cancer nutrition is never about fault, restriction, or control. Cancer is complex, multifactorial, and deeply personal.

Instead, this perspective emphasizes supporting the body’s innate capacity for resilience by creating conditions that encourage metabolic stability and cellular health.

Nutritional needs during cancer are highly individual and depend on many factors, including:

• Treatment type and timing
• Nutritional status and muscle mass
• Metabolic health
• Physical and emotional capacity

When nutrition is approached thoughtfully and compassionately, it becomes a way to partner with the body, rather than overwhelm it.

Key Takeaways

• Cancer involves metabolic dysfunction, not just genetics
• Diet influences blood sugar, insulin, inflammation, and cellular energy
• Metabolic nutrition aims to support healthy cells while challenging cancer metabolism
• Research supports diet as a meaningful complement to conventional care
• Individualized, compassionate guidance is essential

References

• Warburg, O. On the Origin of Cancer Cells. Science.
• Seyfried, T. N., et al. Cancer as a Metabolic Disease. Nutrition & Metabolism.
• Vander Heiden, M. G., et al. Understanding the Warburg Effect. Science.
• Fine, E. J., et al. Targeting Insulin Inhibition as a Metabolic Therapy in Advanced
Cancer. Nutrition.
• Klement, R. J., & Champ, C. E. Calories, Carbohydrates, and Cancer Therapy. Nutrition
& Metabolism.

The Joe Tippens Protocol is an alternative cancer regimen popularized by Joe Tippens, an American who was diagnosed with stage IV small-cell lung cancer in 2016. At the time, his prognosis was extremely poor, with doctors estimating a survival window of just months. Tippens was enrolled in a clinical trial for pembrolizumab (Keytruda), an immunotherapy drug, but he credits much of his remarkable recovery (achieving full remission and remaining cancer-free for over a decade as of 2026) to an unconventional add-on approach he adopted.

Inspired by a veterinarian’s suggestion and preclinical ideas about repurposed drugs, he began self-administering fenbendazole, a benzimidazole anthelmintic primarily used as a veterinary dewormer for parasites in animals. The core protocol typically involves taking approximately 222 mg of fenbendazole daily, sometimes cycled as three days on and four days off, combined with additional supportive supplements. These include bioavailable curcumin, CBD oil, and occasionally vitamin E or other additions like black cumin seed oil in variations. Tippens shared his story through his blog and on social media, sparking widespread interest and anecdotal reports from others who adopted similar regimens for various cancers, including lung, colorectal, pancreatic, prostate, and more.

While Tippens has remained active in discussing his experience and is confirmed alive and in remission in 2026, the protocol has evolved through online communities. I often encounter clients who ask about or have already self-started some version of the Joe Tippens protocol with some users adjusting doses or adding other anthelmintics like ivermectin. The truth about what I have personally seen in my experience as a cancer consultant despite the new encouraging science that has been done on repurposing these drugs for cancer is that the vast majority of these people do not see the same success that Joe Tippens did during his treatment, and almost none of these clients are aware that Joe Tippens was also taking Keytruda, which is now an approved conventional immunotherapy treatment.

The protocol is not a formally approved medical treatment, and Tippens has emphasized it as a personal story rather than universal advice, yet it has gained traction among those seeking options beyond conventional therapies.

The mechanisms of the Joe Tippens protocol in cancer are complex and multifactorial. I tried to keep it light here, but if you don’t want to geek out on the science you may want to skip this paragraph and move on to the next one. The purported mechanisms of the Joe Tippens protocol center primarily on fenbendazole’s potential anticancer effects, drawing from preclinical (in vitro and animal) studies on benzimidazoles. Fenbendazole is believed to disrupt microtubules by binding to β-tubulin, interfering with the formation of the mitotic spindle essential for cell division.

This leads to mitotic arrest (disruption of cell division/proliferation) in rapidly proliferating cancer cells, ultimately triggering apoptosis (programmed cell death), a process very similar to how certain chemotherapy agents like vincristine or paclitaxel function. Additional proposed actions include impairing glucose metabolism due to cancers’ heavy reliance on glycolysis (the Warburg effect) by blocking glucose uptake and reducing energy production, effectively starving tumors of fuel (specifically glucose/sugar which can be augmented with a ketogenic or other low-carb diet). Studies suggest fenbendazole may also induce oxidative stress, activate pathways like p53, interfere with mitochondrial function, and potentially inhibit angiogenesis (new blood vessel formation in tumors). Complementary supplements are thought to enhance these effects synergistically: curcumin modulates inflammatory and signaling pathways (e.g., NF-κB inhibition) that promote cancer survival, while CBD oil may support immune modulation, reduce inflammation, or aid in apoptosis.

In anecdotal accounts, including Tippens’ own narrative, this multi-pronged approach (fenbendazole as the primary agent plus supplements) is credited with tumor regression, improved scans, and sustained remission, even in advanced or treatment-resistant cases. Preclinical data on related benzimidazoles like mebendazole, and other anthelmintics like ivermectin show similar promise across cancer types, and some recent studies over the last few years have explored other beneficial mechanisms like ferroptosis, pyroptosis, or glycolysis suppression via hexokinase 2 downregulation among others. Proponents argue the protocol targets cancer metabolism and cellular infrastructure in ways that standard treatments might not, offering a low-cost, accessible option. However, these mechanisms remain largely hypothetical in humans (outside of anecdotal evidence like from Joe Tippens himself), are derived from lab and animal models rather than controlled clinical evidence, and generally do not include the fact that Tippens’ outcome occurred alongside immunotherapy, complicating attribution to the protocol alone at a minimum.

Despite the compelling anecdotes and preclinical intrigue, the Joe Tippens Protocol is not right for everyone with cancer, and self-administration carries significant risks that demand caution. Foremost among these is the potential for liver toxicity (hepatotoxicity), as fenbendazole and Ivermectin are metabolized primarily in the liver. My personal experience with clients who choose to self-guide the Joe Tippens protocol generally reflect the same patterns (although most of them less severe) of many case reports in the scientific literature documenting severe hepatocellular injury, including jaundice, elevated liver enzymes, and acute liver failure-like presentations, resolving only after discontinuation. For instance, an 80-year-old woman with non-small cell lung cancer developed profound liver damage after one month of use, while other oncology patients on immunotherapy experienced similar issues that mimicked drug-related hepatitis. Individuals with pre-existing impaired liver function common in cancers like hepatocellular carcinoma, metastatic disease affecting the liver, or those with cirrhosis, hepatitis, or prior chemotherapy are particularly vulnerable, as reduced hepatic clearance can lead to drug accumulation, amplified toxicity, and irreversible harm.

Surveys of users in regions like South Korea have noted liver abnormalities in a subset of self-administering patients, alongside gastrointestinal issues and potential hematological effects. Higher or prolonged doses that often occur with self-guided care will exacerbate these risks, and interactions with conventional treatments (e.g., chemotherapy or immunotherapy) remain poorly understood. Moreover, I would argue that without robust human clinical trial data the protocol risks delaying or interfering with evidence-based therapies that offer proven survival benefits. This is true regardless of one’s personal choice to engage in conventional treatment, metabolic terrain-based complementary/alternative treatment, or the integrative model which utilizes both. Organizations like the American Cancer Society and FDA (although generally not my favorite groups) rightly emphasize the absence of controlled data, warning against false hope and potential progression of disease that can occur due primarily to delayed onset of organized treatment, and lack of clinical oversight.

Although oncologists do monitor liver function tests (e.g., ALT, AST, bilirubin), they are largely hesitant to be onboard with or recommend the Joe Tippens protocol as they would then be responsible for adjusting for comorbidities, screening for interactions, and integrating any experimental use safely within a broader plan. In the current medical environment (post-covid era), there are multiple additional concerns a conventional clinician must consider with using off-label drugs including political/institutional kick-back, the lack of human data, and ignorance over compassionate use or complementary and alternative medicine use laws which are designed to ensure informed consent (which is definitely a good thing), but can also be quite clunky and confusing to navigate, especially for those in an institutional setting. If this is the case, it is absolutely essential to find a second opinion or functional consultant/clinician who can regularly assess your lab data in order to keep you out of harm’s way.

In short, the Joe Tippens protocol is circulating widely in the online environment largely due to a lack of trust in the conventional medical models’ approach to cancer, but relying solely on anecdotal success stories overlooks the necessary nuanced individual variability perspective in cancer biology, metabolism, and tolerance. While the protocol inspires hope and highlights drug repurposing potential, it is not a substitute for personalized, medically supervised care. Cancer treatment decisions should prioritize evidence, safety, and professional guidance to avoid unintended harm. So, is the Joe Tippens protocol right for you? Maybe… but maybe not. If you’re curious about finding out more about this and other topics in cancer, consider scheduling a consultation at worldviewwellness.com

IDCT is a personalized cancer treatment that leverages the body’s immune system through the activation of dendritic cells to fight cancer more effectively. Importantly, it is not enough to just use dendritic cells, but to use them correctly if a complete and optimal immune response is desired. That includes Immunocine’s patented “double loading” technology, which has been validated by multiple peer reviewed scientific and medical publications, issued patents, and FDA-sanctioned clinical trials (which has led to a “Fast Track” opportunity in the US).

Science Behind IDCT

Detailed information on how dendritic cells, a type of immune cell, are used in IDCT. Dendritic cells have been studied since the 1970’s, and are well accepted as the “generals” of the immune system “army.” It is their job to detect and identify threats, and then orchestrate the optimal physiological immune response to eliminate it. In the case of cancer, immune ignorance has unfortunately occurred, in which the immune system and its dendritic cells are simply unaware of the threat. A person’s best defense is literally sitting on the sideline. The Immunocine science is not about what is added to the dendritic cells to activate them, but how it is added. The target (the patient’s cancer DNA) needs to be introduced to the patient’s dendritic cells—both internally and externally—at the same time, to activate a natural mechanism in which the dendritic cells become educated, activated, and enlightened to the threat that needs to be eliminated with a Th1 immune response (e.g., the response needed to eliminate infected or mutated cells). This process sounds simplistic, and in a sense, it is (because it is in fact basic biology). But the process is quite complex, fine-tuned, tightly controlled, and not something anyone else can do.

A few components to the Immunocine process are:

• The dendritic cells are extracted from the patient and are properly skewed towards a Th1 phenotype
• The dendritic cells are uniquely ‘double loaded’ with the patient’s tumor material,which leads to a uniquely and optimally educated and activated result
• The dendritic cells are introduced back into the patient, near functional and draining lymph nodes. The dendritic cells are introduced following well established immune kinetics
• A population of ‘killer’ cells are stimulated from these unique dendritic cells and a heightened immune ‘memory’ is resultant from this treatment

Benefits of IDCT

The only thing we know of that can be specific enough to try and counteract a tumor population is the patient’s own immune system. Blunt objects like chemotherapy are typically incapable of this due to a different mechanism of action. Most treatments are mono-focused, looking at one antigen, one receptor, or one whatever. But as cancer learns what is being targeted, it can get rid of it, and thus become invisible again. Dendritic cells are capable of broadly targeting multiple neoantigens expressed by a tumor. This makes it harder for cancer to become invisible again. Chemotherapies are designed typically to kill off dividing cells. Because cancers are rapidly dividing, this type of treatment can delay or prevent that cancer growth. But of course, this also inhibits the division and proliferation of healthy cells, causing collateral damage. Radiation is blunt by design and can easily miss cancer cells. These older and conventional treatments can be helpful, and they were very helpful in Justin’s case, but cancer patients benefit from dendritic cell activation because the older treatments do nothing to educate the patient’s defense system against the cancer. IDCT is currently available in the USA in clinical trials for a select few types of cancer. It will take years for the treatment to get out of the clinical trial phase, it is also important to note that IDCT is not able to treat blood cancers, but it is available to treat all “solid tumor” cancers at Immunocine’s cancer center in Cancun Mexico, where Justin was treated.